undamentalytics Newsletter

Kaltenbach Patrick: insider trades

Chief executive, Officer at 3 companies we cover. 1 open-market purchase and 19 sales not made under a pre-set plan, reported from February 23, 2015 to August 31, 2026.

Would copying Kaltenbach Patrick’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 1 purchase has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on February 22, 2021 into $15,319 by November 2, 2026, +7.8% a year. The copy held shares only 18% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $13,716, +5.7% a year (the S&P 500 held throughout made $21,102, +14.1% a year). Beta against the index was 0.14. Twelve months after each report, the average purchase was +11.2% against the S&P 500 (median +11.2%), and 100% beat it. Measured from the trade date, the insider’s own timing, the average was +7.4%. After their sales, the shares moved −0.8% against the index over 12 months on average (a negative figure means selling was the right call); 65% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$10.0k$20.0k 202120222023202420252026 $21.1k$15.3k$13.7k
Copying Kaltenbach PatrickS&P 500, same days investedS&P 500, held throughout $10,000 copying Kaltenbach Patrick’s open-market purchases from February 22, 2021, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+7.8%
S&P 500, same days invested
+5.7% (held throughout +14.1%)
Time in shares
18%
Sharpe ratio (S&P 500)
0.45 (0.66)
Biggest drop (S&P 500)
−18% (−25%)
Market sensitivity (beta)
0.14
Purchases copied
1

Trade by trade

Kaltenbach Patrick: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 1 +5.6% +5.6% 100% 1 — — Not enough years
Purchases, 6 months after the report 1 +20.4% +20.4% 100% 1 — — Not enough years
Purchases, 12 months after the report 1 +11.2% +11.2% 100% 1 — — Not enough years
Purchases, 12 months after the trade 1 +7.4% +7.4% 100% 1 — — Not enough years
Sales, 3 months after the report 18 −1.8% −4.2% 61% 6 −2.04 0.097 No reliable evidence
Sales, 12 months after the report 17 −0.8% −3.0% 65% 5 0.46 0.67 No reliable evidence
Sales, 12 months after the trade 17 −1.5% −3.0% 65% 5 0.38 0.72 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Agilent Technologies A Sr Vice President011February 23, 2015March 29, 2018
Becton Dickinson BDX EVP & Pres Life Sciences06June 5, 2019December 16, 2019
Mettler Toledo MTD President and CEO12February 19, 2021August 31, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 31, 2026August 27, 2026 MTD Sale $1,342,350 not yetnot yetnot yet
November 13, 2025November 12, 2025 MTD Sale $2,924,998 −4.4%not yetnot yet
February 19, 2021February 17, 2021 MTD Purchase $58,500 +5.6%+11.2%+7.4%
December 16, 2019December 12, 2019 BDX Sale $89,235 +6.8%−25.7%−25.1%
December 6, 2019December 6, 2019 BDX Sale $81,591 +2.4%−26.1%−27.6%
August 12, 2019August 9, 2019 BDX Sale $32,230 −9.9%−14.8%−15.1%
August 9, 2019August 8, 2019 BDX Sale $98,620 −9.2%−14.2%−13.0%
June 11, 2019June 10, 2019 BDX Sale $46,037 +5.9%−8.0%−13.2%
June 5, 2019June 4, 2019 BDX Sale $64,625 +4.2%−11.2%−8.9%
March 29, 2018March 29, 2018 A Sale $269,120 −9.9%+13.9%+12.6%
March 14, 2018March 12, 2018 A Sale $490,738 −7.1%+11.4%+11.4%
November 29, 2017November 28, 2017 A Sale $347,800 −5.5%−0.5%−4.2%
November 27, 2017November 22, 2017 A Sale $509,785 −6.7%−4.2%−3.0%
June 1, 2017May 31, 2017 A Sale $125,332 +4.8%−9.6%−10.8%
February 21, 2017February 16, 2017 A Sale $194,885 +12.5%+22.2%+24.2%
October 3, 2016September 30, 2016 A Sale $94,600 −5.3%+21.6%+20.1%
September 1, 2016August 31, 2016 A Sale $94,000 −7.2%+23.2%+23.0%
May 20, 2016May 19, 2016 A Sale $232,073 0.0%+13.6%+8.2%
March 4, 2015March 3, 2015 A Sale $48,729 −4.0%−3.0%−2.8%
February 23, 2015February 19, 2015 A Sale $45,441 +0.3%−3.0%−1.4%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Kaltenbach Patrick traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.